Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
control group 1:Lopinavir / Ritonavir (Kaletra) and IFN aerosol inhalation
control group 2:Abidol and IFN aerosol inhalation.
Experimental group:ASC09/ Ritonavir (ASC09F) and IFN aerosol inhalation
Sponsors
The Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18- 80 years old; 2. Pneumonia patients with new coronavirus infection were confirmed to be positive by RT-PCR and clinical manifestations. The diagnosis standard refers to the diagnosis and treatment plan for pneumonia with new coronavirus infection (trial version 5); 3. Patients with newly diagnosed respiratory system discomfort who have been hospitalized (the diagnosis time of respiratory system discomfort shall not exceed 7 days); 4. Women and their partners who have no planned pregnancy for nearly half a year and are willing to take effective contraceptive measures within 30 days from the first administration of the study drug to the last administration; 5. Agree not to participate in other clinical research within 30 days from the first administration of the study drug to the last administration; 6. Patients who voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe liver disease (such as child Pugh score >= C, AST > 5 times upper limit); 2. The patients were allergic to the components in asc09 / ritonavir compound tablets; 3. Patients with contraindications specified in the instructions of ritonavir tablets; 4. The pregnancy test of female subjects in the screening period was positive; 5. Patients have treat with HIV protease inhibitor; 6. The researchers judged that it was not suitable to participate in this clinical trial (for example, patients who may be transferred to another hospital during the study period; patients with multiple basic diseases, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to recovery.; | — |
Secondary
| Measure | Time frame |
|---|---|
| rate of composite advers outcomes.;rate of no fever (Time Frame: 14 days);rate of no cough;rate of no dyspnea;rate of no requring supplemental oxygen;rate of undectable New coronavirus pathogen nucleic acid;rate of mechanical ventilation;rate of ICU admission; | — |
Countries
China
Contacts
Public ContactPeng Hu
The Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed